UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation
In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.
In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”
Abbott Laboratories closed on Tuesday at $36.55.
Latest Ratings for ABT
|Apr 2016||Piper Jaffray||Downgrades||Overweight||Neutral|
|Feb 2016||Argus Research||Upgrades||Hold||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.